UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Several technologies for hemoglobinopathies are being transferred to commercial partners
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
Subscribe To Our Newsletter & Stay Updated
